JP2013529070A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013529070A5 JP2013529070A5 JP2013505070A JP2013505070A JP2013529070A5 JP 2013529070 A5 JP2013529070 A5 JP 2013529070A5 JP 2013505070 A JP2013505070 A JP 2013505070A JP 2013505070 A JP2013505070 A JP 2013505070A JP 2013529070 A5 JP2013529070 A5 JP 2013529070A5
- Authority
- JP
- Japan
- Prior art keywords
- scaffold
- seq
- multimeric
- multimeric scaffold
- monomer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000178 monomer Substances 0.000 claims 10
- 238000000034 method Methods 0.000 claims 6
- 108090000765 processed proteins & peptides Proteins 0.000 claims 5
- 101100369992 Homo sapiens TNFSF10 gene Proteins 0.000 claims 4
- 239000002202 Polyethylene glycol Substances 0.000 claims 4
- 102000046283 TNF-Related Apoptosis-Inducing Ligand Human genes 0.000 claims 4
- 108700012411 TNFSF10 Proteins 0.000 claims 4
- 229920001223 polyethylene glycol Polymers 0.000 claims 4
- 125000000539 amino acid group Chemical group 0.000 claims 3
- 102000039446 nucleic acids Human genes 0.000 claims 3
- 108020004707 nucleic acids Proteins 0.000 claims 3
- 150000007523 nucleic acids Chemical class 0.000 claims 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 102000004196 processed proteins & peptides Human genes 0.000 claims 2
- 108010088751 Albumins Proteins 0.000 claims 1
- 102000009027 Albumins Human genes 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 102000004127 Cytokines Human genes 0.000 claims 1
- 108090000695 Cytokines Proteins 0.000 claims 1
- 108090000790 Enzymes Proteins 0.000 claims 1
- 102000004190 Enzymes Human genes 0.000 claims 1
- 102000008100 Human Serum Albumin Human genes 0.000 claims 1
- 108091006905 Human Serum Albumin Proteins 0.000 claims 1
- 102100026120 IgG receptor FcRn large subunit p51 Human genes 0.000 claims 1
- 101710177940 IgG receptor FcRn large subunit p51 Proteins 0.000 claims 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 208000034578 Multiple myelomas Diseases 0.000 claims 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 238000011374 additional therapy Methods 0.000 claims 1
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 230000006907 apoptotic process Effects 0.000 claims 1
- 238000001815 biotherapy Methods 0.000 claims 1
- 229960002685 biotin Drugs 0.000 claims 1
- 235000020958 biotin Nutrition 0.000 claims 1
- 239000011616 biotin Substances 0.000 claims 1
- 238000002512 chemotherapy Methods 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 239000002872 contrast media Substances 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 231100000433 cytotoxic Toxicity 0.000 claims 1
- 230000001472 cytotoxic effect Effects 0.000 claims 1
- 238000002651 drug therapy Methods 0.000 claims 1
- 239000013604 expression vector Substances 0.000 claims 1
- 238000009169 immunotherapy Methods 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 229920000592 inorganic polymer Polymers 0.000 claims 1
- 239000003446 ligand Substances 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 229920000620 organic polymer Polymers 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 229920000642 polymer Polymers 0.000 claims 1
- 229920001184 polypeptide Polymers 0.000 claims 1
- 108020001580 protein domains Proteins 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 230000002285 radioactive effect Effects 0.000 claims 1
- 238000001959 radiotherapy Methods 0.000 claims 1
- 239000000018 receptor agonist Substances 0.000 claims 1
- 229940044601 receptor agonist Drugs 0.000 claims 1
- 229940126586 small molecule drug Drugs 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 239000003053 toxin Substances 0.000 claims 1
- 231100000765 toxin Toxicity 0.000 claims 1
- 108700012359 toxins Proteins 0.000 claims 1
- 239000013598 vector Substances 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US32370810P | 2010-04-13 | 2010-04-13 | |
| US61/323,708 | 2010-04-13 | ||
| PCT/US2011/032188 WO2011130328A1 (en) | 2010-04-13 | 2011-04-12 | Trail r2-specific multimeric scaffolds |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013529070A JP2013529070A (ja) | 2013-07-18 |
| JP2013529070A5 true JP2013529070A5 (enExample) | 2014-04-10 |
| JP6041799B2 JP6041799B2 (ja) | 2016-12-14 |
Family
ID=44799000
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013505069A Pending JP2013523179A (ja) | 2010-04-13 | 2011-04-12 | フィブロネクチンタイプｉｉｉドメインに基づく多量体足場 |
| JP2013505070A Active JP6041799B2 (ja) | 2010-04-13 | 2011-04-12 | Ｔｒａｉｌｒ２特異的多量体足場 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013505069A Pending JP2013523179A (ja) | 2010-04-13 | 2011-04-12 | フィブロネクチンタイプｉｉｉドメインに基づく多量体足場 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US20130079280A1 (enExample) |
| EP (2) | EP2560684A4 (enExample) |
| JP (2) | JP2013523179A (enExample) |
| KR (2) | KR20130056870A (enExample) |
| CN (2) | CN102906112B (enExample) |
| AU (2) | AU2011240624B2 (enExample) |
| BR (1) | BR112012026003B1 (enExample) |
| CA (2) | CA2796010C (enExample) |
| ES (1) | ES2755398T3 (enExample) |
| MX (1) | MX341119B (enExample) |
| RU (1) | RU2628699C2 (enExample) |
| SG (2) | SG184185A1 (enExample) |
| WO (2) | WO2011130324A1 (enExample) |
Families Citing this family (98)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2402567C2 (ru) | 2003-12-05 | 2010-10-27 | Бристоль-Майерз Сквибб Компани | Ингибиторы рецепторов фактора роста эндотелия сосудов типа 2 |
| AU2007325838B2 (en) | 2006-11-22 | 2013-09-19 | Bristol-Myers Squibb Company | Targeted therapeutics based on engineered proteins for tyrosine kinases receptors, including IGF-IR |
| MX2010008874A (es) | 2008-02-14 | 2010-09-22 | Bristol Myers Squibb Co | Terapeuticos dirigidos a base de proteinas manipuladas que se unen al receptor de factor de crecimiento epidermico. |
| EP2291399B1 (en) | 2008-05-22 | 2014-06-25 | Bristol-Myers Squibb Company | Multivalent fibronectin based scaffold domain proteins |
| TWI496582B (zh) | 2008-11-24 | 2015-08-21 | 必治妥美雅史谷比公司 | 雙重專一性之ｅｇｆｒ／ｉｇｆｉｒ結合分子 |
| AU2011240624B2 (en) * | 2010-04-13 | 2017-02-23 | Medimmune, Llc | TRAIL R2-specific multimeric scaffolds |
| TW201138808A (en) | 2010-05-03 | 2011-11-16 | Bristol Myers Squibb Co | Serum albumin binding molecules |
| ES2573108T3 (es) | 2010-05-26 | 2016-06-06 | Bristol-Myers Squibb Company | Proteínas de armazón a base de fibronectina que tienen estabilidad mejorada |
| SI2697257T1 (sl) | 2011-04-13 | 2017-02-28 | Bristol-Myers Squibb Company | FC fuzijski proteini, ki vsebujejo nove linkerje ali razmestitve |
| US20140187488A1 (en) | 2011-05-17 | 2014-07-03 | Bristol-Myers Squibb Company | Methods for maintaining pegylation of polypeptides |
| WO2012158739A1 (en) | 2011-05-17 | 2012-11-22 | Bristol-Myers Squibb Company | Improved methods for the selection of binding proteins |
| DK2771022T3 (da) | 2011-10-11 | 2020-09-28 | Viela Bio Inc | Cd40l-specifikke tn3-afledte skeletter (scaffolds) og fremgangsmåder til anvendelse deraf |
| JP2015504038A (ja) | 2011-10-31 | 2015-02-05 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | 低減した免疫原性を有するフィブロネクチン結合ドメイン |
| CN103906533A (zh) | 2011-11-07 | 2014-07-02 | 米迪缪尼有限公司 | 多特异性和多价结合蛋白及其用途 |
| RS57480B1 (sr) | 2011-11-08 | 2018-10-31 | Umc Utrecht Holding Bv | Fuzioni protein koji sadrži interleukin 4 i interleukin 10 |
| WO2014043344A1 (en) | 2012-09-13 | 2014-03-20 | Bristol-Myers Squibb Company | Fibronectin based scaffold domain proteins that bind to myostatin |
| US9695228B2 (en) | 2012-11-21 | 2017-07-04 | Janssen Biotech, Inc. | EGFR and c-Met fibronectin type III domain binding molecules |
| EP2951206A2 (en) * | 2013-02-01 | 2015-12-09 | Bristol-Myers Squibb Company | Fibronectin based scaffold proteins |
| EP2953968B1 (en) | 2013-02-06 | 2018-07-25 | Bristol-Myers Squibb Company | Fibronectin type iii domain proteins with enhanced solubility |
| ES2751735T3 (es) | 2013-02-12 | 2020-04-01 | Bristol Myers Squibb Co | Métodos de replegado de proteínas a elevado pH |
| WO2014126871A1 (en) | 2013-02-12 | 2014-08-21 | Bristol-Myers Squibb Company | Tangential flow filtration based protein refolding methods |
| WO2014165093A2 (en) | 2013-03-13 | 2014-10-09 | Bristol-Myers Squibb Company | Fibronectin based scaffold domains linked to serum albumin or a moiety binding thereto |
| PL2970473T3 (pl) | 2013-03-14 | 2018-01-31 | Bristol Myers Squibb Co | Kombinacja agonisty dr5 i antagonisty anty-pd-1 oraz metody stosowania |
| US10392611B2 (en) | 2013-05-30 | 2019-08-27 | Duke University | Polymer conjugates having reduced antigenicity and methods of using the same |
| US10364451B2 (en) | 2013-05-30 | 2019-07-30 | Duke University | Polymer conjugates having reduced antigenicity and methods of using the same |
| KR102478402B1 (ko) | 2013-10-14 | 2022-12-15 | 얀센 바이오테크 인코포레이티드 | 시스테인 조작된 피브로넥틴 iii형 도메인 결합 분자 |
| WO2015138638A1 (en) | 2014-03-11 | 2015-09-17 | Theraly Pharmaceuticals, Inc. | Long acting trail receptor agonists for treatment of autoimmune diseases |
| WO2015143156A1 (en) | 2014-03-20 | 2015-09-24 | Bristol-Myers Squibb Company | Stabilized fibronectin based scaffold molecules |
| KR102472862B1 (ko) | 2014-03-20 | 2022-12-05 | 브리스톨-마이어스 스큅 컴퍼니 | 혈청 알부민-결합 피브로넥틴 유형 iii 도메인 |
| WO2015148269A2 (en) * | 2014-03-24 | 2015-10-01 | Medimmune, Llc | Stabilized tnfn3 scaffold proteins |
| NO2776305T3 (enExample) * | 2014-04-23 | 2018-01-27 | ||
| US10562946B2 (en) * | 2014-06-20 | 2020-02-18 | Genentech, Inc. | Chagasin-based scaffold compositions, methods, and uses |
| CA2962783A1 (en) | 2014-10-01 | 2016-04-07 | Medimmune, Llc | Method of conjugating a polypeptide |
| EP4218832A3 (en) | 2014-11-25 | 2023-08-23 | Bristol-Myers Squibb Company | Methods and compositions for 18f-radiolabeling of the fibronectin type (iii) domain |
| US10683340B2 (en) | 2015-03-12 | 2020-06-16 | Medimmune, Llc | Method of purifying albumin-fusion proteins |
| US10385115B2 (en) | 2015-03-26 | 2019-08-20 | Duke University | Fibronectin type III domain-based fusion proteins |
| MA42059A (fr) | 2015-05-06 | 2018-03-14 | Janssen Biotech Inc | Agents de liaison bispécifique à l'antigène membranaire spécifique de la prostate (psma) et utilisations de ceux-ci |
| JP6882782B2 (ja) | 2015-08-04 | 2021-06-02 | デューク ユニバーシティ | 遺伝子コードされた本質的に無秩序な送達用ステルスポリマーおよびその使用方法 |
| WO2017048709A1 (en) | 2015-09-14 | 2017-03-23 | Arizona Board Of Regents On Behalf Of Arizona State University | Generating recominant affinity reagents with arrayed targets |
| EP3733698A1 (en) | 2015-09-23 | 2020-11-04 | Bristol-Myers Squibb Company | Glypican-3 binding fibronectin based scafflold molecules |
| EP3353199B1 (en) | 2015-09-23 | 2020-02-19 | Bristol-Myers Squibb Company | Fast-off rate serum albumin binding fibronectin type iii domains |
| CN108699110B (zh) | 2015-10-23 | 2023-04-28 | 特温特大学 | 整合素结合肽及其用途 |
| WO2017106627A1 (en) | 2015-12-17 | 2017-06-22 | The Johns Hopkins University | Ameliorating systemic sclerosis with death receptor agonists |
| US11752213B2 (en) | 2015-12-21 | 2023-09-12 | Duke University | Surfaces having reduced non-specific binding and antigenicity |
| EP3439687A1 (en) | 2016-04-07 | 2019-02-13 | The Johns Hopkins University | Compositions and methods for treating pancreatitis and pain with death receptor agonists |
| AR108377A1 (es) | 2016-05-06 | 2018-08-15 | Medimmune Llc | Proteínas de unión biespecíficas y sus usos |
| CN105802970A (zh) * | 2016-05-30 | 2016-07-27 | 东北师范大学 | 靶向沉默Gβ1的shRNA |
| US10994033B2 (en) | 2016-06-01 | 2021-05-04 | Bristol-Myers Squibb Company | Imaging methods using 18F-radiolabeled biologics |
| US11467156B2 (en) | 2016-06-01 | 2022-10-11 | Duke University | Nonfouling biosensors |
| EA201990067A1 (ru) | 2016-06-21 | 2019-07-31 | Янссен Байотек, Инк. | Цистеин-модифицированные связывающие молекулы на основе домена фибронектина iii типа |
| EP3512868A4 (en) | 2016-09-14 | 2020-04-15 | Duke University | NANOPARTICLES BASED ON TRIBLOCK POLYPEPTIDE FOR THE DELIVERY OF HYDROPHILIC DRUGS |
| JP2020500150A (ja) | 2016-09-23 | 2020-01-09 | デューク ユニバーシティ | 下限臨界溶液温度挙動を有する非反復かつ非構造的ポリペプチド |
| WO2018111976A1 (en) | 2016-12-14 | 2018-06-21 | Janssen Biotech, Inc. | Pd-l1 binding fibronectin type iii domains |
| EP3554561B1 (en) | 2016-12-14 | 2023-06-28 | Janssen Biotech, Inc. | Cd137 binding fibronectin type iii domains |
| JP7104703B2 (ja) | 2016-12-14 | 2022-07-21 | ヤンセン バイオテツク，インコーポレーテツド | Ｃｄ８ａ結合フィブロネクチンｉｉｉ型ドメイン |
| WO2018132732A1 (en) | 2017-01-12 | 2018-07-19 | Duke University | Genetically encoded lipid-polypeptide hybrid biomaterials that exhibit temperature triggered hierarchical self-assembly |
| US10787499B2 (en) * | 2017-02-13 | 2020-09-29 | Regents Of The University Of Minnesota | EpCAM targeted polypeptides, conjugates thereof, and methods of use thereof |
| WO2018213320A1 (en) | 2017-05-15 | 2018-11-22 | Duke University | Recombinant production of hybrid lipid-biopolymer materials that self-assemble and encapsulate agents |
| AR111963A1 (es) | 2017-05-26 | 2019-09-04 | Univ California | Método y moléculas |
| US11680083B2 (en) | 2017-06-30 | 2023-06-20 | Duke University | Order and disorder as a design principle for stimuli-responsive biopolymer networks |
| WO2019147954A1 (en) | 2018-01-26 | 2019-08-01 | Duke University | Albumin binding peptide-drug (aibiped) conjugates and methods of making and using same |
| US11491206B1 (en) | 2018-02-13 | 2022-11-08 | Duke University | Compositions and methods for the treatment of trail-resistant cancer |
| WO2019165017A1 (en) * | 2018-02-23 | 2019-08-29 | The University Of Chicago | Methods and composition involving thermophilic fibronectin type iii (fn3) monobodies |
| EP3788343B1 (en) | 2018-04-30 | 2024-03-27 | Duke University | Stimuli-responsive peg-like polymer-based drug delivery platform |
| CA3098420A1 (en) | 2018-06-01 | 2019-12-05 | Novartis Ag | Binding molecules against bcma and uses thereof |
| CN110724198B (zh) * | 2018-07-17 | 2023-05-26 | 上海一宸医药科技有限公司 | 长效纤连蛋白iii型结构域融合蛋白 |
| WO2020028806A1 (en) | 2018-08-02 | 2020-02-06 | Duke University | Dual agonist fusion proteins |
| US11986536B2 (en) | 2019-03-23 | 2024-05-21 | Ablevia Biotech Gmbh | Compound for the sequestration of undesirable antibodies in a patient |
| EP3715376A1 (en) | 2019-03-23 | 2020-09-30 | Ablevia biotech GmbH | Compound for the prevention or treatment of myasthenia gravis |
| EP3715374A1 (en) | 2019-03-23 | 2020-09-30 | Ablevia biotech GmbH | Compound for the sequestration of undesirable antibodies in a patient |
| EP4545139A3 (en) | 2019-04-19 | 2025-07-09 | Synerkine Pharma B.V. | A fusion protein comprising il13 |
| WO2020236797A1 (en) | 2019-05-21 | 2020-11-26 | Novartis Ag | Variant cd58 domains and uses thereof |
| CR20210576A (es) | 2019-05-21 | 2021-12-15 | Novartis Ag | Moléculas de unión a cd19 y usos de las mismas |
| CN114173810B (zh) | 2019-05-21 | 2024-09-06 | 诺华股份有限公司 | 针对bcma的三特异性结合分子及其用途 |
| US11512314B2 (en) | 2019-07-12 | 2022-11-29 | Duke University | Amphiphilic polynucleotides |
| JP7772687B2 (ja) | 2019-07-15 | 2025-11-18 | メディミューン リミテッド | タンパク質二量体化の三分子システム及び使用方法 |
| US12491255B2 (en) | 2019-10-14 | 2025-12-09 | Aro Biotherapeutics Company | EPCAM binding fibronectin type III domains |
| CN114786682B (zh) | 2019-10-14 | 2024-07-16 | Aro生物疗法公司 | 结合cd71的纤维粘连蛋白iii型结构域 |
| WO2021076574A2 (en) | 2019-10-14 | 2021-04-22 | Aro Biotherapeutics Company | Fn3 domain-sirna conjugates and uses thereof |
| CN111217903B (zh) * | 2020-02-25 | 2022-11-15 | 芜湖天明生物技术有限公司 | 一种重组人纤连蛋白ⅲ1-c及其制备方法和应用 |
| WO2021174045A1 (en) | 2020-02-28 | 2021-09-02 | Bristol-Myers Squibb Company | Radiolabeled fibronectin based scaffolds and antibodies and theranostic uses thereof |
| JP2023520773A (ja) | 2020-03-27 | 2023-05-19 | ノバルティス アーゲー | 増殖性疾患及び自己免疫疾患を治療するための二重特異性組合せ治療 |
| US11767353B2 (en) | 2020-06-05 | 2023-09-26 | Theraly Fibrosis, Inc. | Trail compositions with reduced immunogenicity |
| CN111944204B (zh) * | 2020-07-24 | 2022-03-08 | 南京理工大学 | 一种Fe3O4磁性细菌纤维素及其制备方法 |
| WO2022063879A1 (en) | 2020-09-23 | 2022-03-31 | Ablevia Biotech Gmbh | Compound for the sequestration of undesirable antibodies in a patient |
| EP4217381A1 (en) | 2020-09-23 | 2023-08-02 | Ablevia biotech GmbH | Compound for increasing the efficacy of factor viii replacement therapy |
| JP2023542389A (ja) | 2020-09-23 | 2023-10-06 | アブレヴィア バイオテック ゲーエムベーハー | 自己抗体で媒介される状態の予防又は治療のための化合物 |
| CN116547008A (zh) | 2020-09-23 | 2023-08-04 | 艾柏力维亚生技有限公司 | 用于增加病毒载体的效力的化合物 |
| TW202228784A (zh) | 2020-09-23 | 2022-08-01 | 奧地利商艾柏力維亞生技有限公司 | 用以於一患者中螯合非預期的抗ｐｅｇ抗體的化合物 |
| AU2021348225A1 (en) | 2020-09-24 | 2023-05-18 | Ablevia Biotech Gmbh | Compound for the prevention or treatment of myasthenia gravis |
| US20250215081A1 (en) | 2020-11-06 | 2025-07-03 | Novartis Ag | Anti-cd19 agent and b cell targeting agent combination therapy for treating b cell malignancies |
| CA3199095A1 (en) | 2020-11-06 | 2022-05-12 | Novartis Ag | Cd19 binding molecules and uses thereof |
| JP2024517610A (ja) | 2021-04-14 | 2024-04-23 | アロ・バイオセラピューティクス・カンパニー | Ｃｄ７１に結合するフィブロネクチンｉｉｉ型ドメイン |
| US12239710B2 (en) | 2021-04-14 | 2025-03-04 | Aro Biotherapeutics Company | FN3 domain-siRNA conjugates and uses thereof |
| AU2023238299A1 (en) | 2022-03-24 | 2024-11-07 | Ablevia Biotech Gmbh | Compound for increasing efficacy of oncolytic viruses |
| KR102459313B1 (ko) * | 2022-04-11 | 2022-10-26 | 주식회사 대영방재산업 | 내구성이 개선된 소방용 수격 흡수기 |
| WO2024261323A1 (en) | 2023-06-23 | 2024-12-26 | Astrazeneca Ab | Molecular switches |
| WO2025125630A1 (en) | 2023-12-15 | 2025-06-19 | Medimmune Limited | Method for bioprotac design |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6482410B1 (en) | 1994-09-16 | 2002-11-19 | The Scripps Research Institute | Cytotactin derivatives that stimulate attachment and neurite outgrowth, and methods of making same |
| EP2380906A2 (en) | 1997-06-12 | 2011-10-26 | Novartis International Pharmaceutical Ltd. | Artificial antibody polypeptides |
| US6160089A (en) | 1998-07-08 | 2000-12-12 | Mitsui Chemicals, Inc. | Method for secretory production of human growth hormone |
| CA2341276C (en) * | 1998-08-28 | 2005-10-11 | Genentech, Inc. | Human anti-factor ix/ixa antibodies |
| JP4562286B2 (ja) | 1998-12-10 | 2010-10-13 | ブリストル−マイヤーズ スクウィブ カンパニー | 抗体模倣物および他の結合タンパク質のタンパク質骨格 |
| US7115396B2 (en) | 1998-12-10 | 2006-10-03 | Compound Therapeutics, Inc. | Protein scaffolds for antibody mimics and other binding proteins |
| US6818418B1 (en) | 1998-12-10 | 2004-11-16 | Compound Therapeutics, Inc. | Protein scaffolds for antibody mimics and other binding proteins |
| JP4578768B2 (ja) | 2000-07-11 | 2010-11-10 | リサーチ コーポレイション テクノロジーズ，インコーポレイテッド | 人工抗体ポリペプチド |
| EP1356075A4 (en) | 2000-10-16 | 2005-04-13 | Compound Therapeutics Inc | PROTEIN EQUIPMENT FOR ANTIBODY MIMETICS AND OTHER TIE PROTEINS |
| EP2339017A3 (en) | 2002-03-29 | 2011-10-12 | Genencor International, Inc. | Enhanced protein expression in bacillus |
| WO2003104418A2 (en) | 2002-06-06 | 2003-12-18 | Research Corporation Technologies, Inc. | Reconstituted polypeptides |
| AU2003247609A1 (en) | 2002-06-24 | 2004-01-06 | Genentech, Inc. | Apo-2 ligand/trail variants and uses thereof |
| RU2402567C2 (ru) | 2003-12-05 | 2010-10-27 | Бристоль-Майерз Сквибб Компани | Ингибиторы рецепторов фактора роста эндотелия сосудов типа 2 |
| EP1710255A4 (en) * | 2003-12-12 | 2008-09-24 | Chugai Pharmaceutical Co Ltd | MODIFIED ANTIBODIES RECOGNIZING A TRIMER OR LARGER RECEPTOR |
| GB0416651D0 (en) | 2004-07-26 | 2004-08-25 | Proteo Target Aps | Polypeptide |
| CN101300273B (zh) * | 2005-08-31 | 2013-05-22 | 安姆根有限公司 | Trail受体2多肽和抗体 |
| US10183986B2 (en) | 2005-12-15 | 2019-01-22 | Industrial Technology Research Institute | Trimeric collagen scaffold antibodies |
| EP1989529A4 (en) * | 2006-02-13 | 2010-09-01 | Agency Science Tech & Res | PROCESS FOR PROCESSING A BIOLOGICAL AND / OR CHEMICAL SAMPLE |
| CN101074261A (zh) * | 2006-04-30 | 2007-11-21 | 北京同为时代生物技术有限公司 | Trail受体1和/或trail受体2特异性抗体及其应用 |
| WO2008031098A1 (en) | 2006-09-09 | 2008-03-13 | The University Of Chicago | Binary amino acid libraries for fibronectin type iii polypeptide monobodies |
| AU2007325838B2 (en) | 2006-11-22 | 2013-09-19 | Bristol-Myers Squibb Company | Targeted therapeutics based on engineered proteins for tyrosine kinases receptors, including IGF-IR |
| AU2008287426B2 (en) | 2007-08-10 | 2014-06-26 | Protelica, Inc. | Universal fibronectin type III binding-domain libraries |
| US8470966B2 (en) | 2007-08-10 | 2013-06-25 | Protelica, Inc. | Universal fibronectin type III binding-domain libraries |
| JP2011501951A (ja) * | 2007-10-31 | 2011-01-20 | メディミューン，エルエルシー | タンパク質足場 |
| WO2009083804A2 (en) | 2007-12-27 | 2009-07-09 | Novartis Ag | Improved fibronectin-based binding molecules and their use |
| US9296810B2 (en) | 2008-05-02 | 2016-03-29 | Novartis Ag | Fibronectin-based binding molecules and uses thereof |
| EP2291399B1 (en) * | 2008-05-22 | 2014-06-25 | Bristol-Myers Squibb Company | Multivalent fibronectin based scaffold domain proteins |
| AU2009303304A1 (en) * | 2008-10-10 | 2010-04-15 | Anaphore, Inc. | Polypeptides that bind TRAIL-RI and TRAIL-R2 |
| HRP20161251T1 (hr) | 2008-10-31 | 2016-11-18 | Janssen Biotech, Inc. | Platformski sastavi zasnovani na domeni fibronektina tipa iii, postupci i upotrebe |
| TWI496582B (zh) | 2008-11-24 | 2015-08-21 | 必治妥美雅史谷比公司 | 雙重專一性之ｅｇｆｒ／ｉｇｆｉｒ結合分子 |
| EP2396011B1 (en) | 2009-02-12 | 2016-04-13 | Janssen Biotech, Inc. | Fibronectin type iii domain based scaffold compositions, methods and uses |
| US20120270797A1 (en) | 2009-08-13 | 2012-10-25 | Massachusetts Institute Of Technology | Engineered proteins including mutant fibronectin domains |
| AU2011240624B2 (en) * | 2010-04-13 | 2017-02-23 | Medimmune, Llc | TRAIL R2-specific multimeric scaffolds |
-
2011
- 2011-04-12 AU AU2011240624A patent/AU2011240624B2/en active Active
- 2011-04-12 KR KR1020127029343A patent/KR20130056870A/ko not_active Withdrawn
- 2011-04-12 ES ES11769481T patent/ES2755398T3/es active Active
- 2011-04-12 RU RU2012147960A patent/RU2628699C2/ru active
- 2011-04-12 CA CA2796010A patent/CA2796010C/en active Active
- 2011-04-12 WO PCT/US2011/032184 patent/WO2011130324A1/en not_active Ceased
- 2011-04-12 AU AU2011240620A patent/AU2011240620A1/en not_active Abandoned
- 2011-04-12 JP JP2013505069A patent/JP2013523179A/ja active Pending
- 2011-04-12 EP EP11769477.8A patent/EP2560684A4/en not_active Withdrawn
- 2011-04-12 CN CN201180018796.8A patent/CN102906112B/zh active Active
- 2011-04-12 CA CA2795325A patent/CA2795325A1/en not_active Abandoned
- 2011-04-12 SG SG2012070108A patent/SG184185A1/en unknown
- 2011-04-12 JP JP2013505070A patent/JP6041799B2/ja active Active
- 2011-04-12 WO PCT/US2011/032188 patent/WO2011130328A1/en not_active Ceased
- 2011-04-12 MX MX2012011840A patent/MX341119B/es active IP Right Grant
- 2011-04-12 EP EP11769481.0A patent/EP2558495B1/en active Active
- 2011-04-12 CN CN2011800187879A patent/CN102834114A/zh active Pending
- 2011-04-12 KR KR1020127029323A patent/KR101747991B1/ko active Active
- 2011-04-12 US US13/640,057 patent/US20130079280A1/en not_active Abandoned
- 2011-04-12 SG SG10201505470QA patent/SG10201505470QA/en unknown
- 2011-04-12 US US13/639,381 patent/US9212231B2/en active Active
- 2011-04-12 BR BR112012026003-0A patent/BR112012026003B1/pt active IP Right Grant
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013529070A5 (enExample) | ||
| RU2012147960A (ru) | Trail r2-специфические мультимерные скаффолды | |
| Lipovšek | Adnectins: engineered target-binding protein therapeutics | |
| Holt et al. | Anti-serum albumin domain antibodies for extending the half-lives of short lived drugs | |
| Stork et al. | A novel tri-functional antibody fusion protein with improved pharmacokinetic properties generated by fusing a bispecific single-chain diabody with an albumin-binding domain from streptococcal protein G | |
| Mujić-Delić et al. | GPCR-targeting nanobodies: attractive research tools, diagnostics, and therapeutics | |
| EP1888641B1 (en) | Serum albumin binding proteins | |
| JP6618463B2 (ja) | 三量体型抗原結合分子 | |
| JP2018512145A5 (enExample) | ||
| US20160376346A1 (en) | Fc FUSION PROTEINS COMPRISING NOVEL LINKERS OR ARRANGEMENTS | |
| Jay et al. | Protein engineering for cardiovascular therapeutics: untapped potential for cardiac repair | |
| US10995142B2 (en) | Monoclonal antibody FnAb8 and application thereof | |
| JP2011501951A5 (enExample) | ||
| JP2021502810A5 (enExample) | ||
| CN113365663A (zh) | 单链嵌合多肽和其用途 | |
| RU2017134140A (ru) | Конструкции, направленные на комплексы пептида аfp/мнс, и виды их использования | |
| JP2017529067A5 (enExample) | ||
| HRP20190472T1 (hr) | Klaudin-6 specifični imunoreceptori i t-stanični epitopi | |
| IL258419A (en) | A new polypeptide with affinity for pd-l1 | |
| Zhang et al. | Functional antibody CDR3 fusion proteins with enhanced pharmacological properties | |
| EP4130046A1 (en) | Platform for constructing multispecific antibody | |
| CN113544144A (zh) | 变体cd80融合蛋白和相关构建体的方法和用途 | |
| JP2020519293A5 (enExample) | ||
| JP2015520172A5 (enExample) | ||
| JP2019511457A5 (enExample) |